Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Tina Tan
Certain VCs are becoming reluctant to invest in medtech, citing difficulties such as a shrinking pool of buyers and increasing regulatory challenges. But Sofinnova Partners has successfully sold a medical device portfolio company – and one that is in a difficult field like renal denervation, no less – to a Japanese buyer. Antoine Papiernik, managing partner at the French VC, explains how persevering with a renal denervation technology paid-off and gives his perspective on whether medtech is still a space worth investing in.
A quartet of mega-rounds in June closed off what has been the most successful first-half since 2014, with an impressive $4.7bn of private venture funds raised in total. Digital health is one area that is evidently rising in investor popularity and potentially helping to drive these mega-rounds.
Swiss Advanced Vision is extending its expertise in intraocular lenses to develop a new line of smart IOLs that automatically focus in real-time to correct presbyopia. These active lenses will also have a remote calibration feature so they can easily be adjusted post-implantation.
In the face of BD’s (Becton Dickinson & Co.) ever-broadening portfolio – bulked up by the group's appetite for billion-dollar acquisitions – the Diagnostic Systems unit remains an important, and currently the strongest, contributor to BD's overall growth story. Dave Hickey, worldwide president of BD Diagnostic Systems, spoke to Medtech Insight about the trends that are driving, as well as limiting, the in vitro diagnostics sector, and how BD is addressing those issues to keep the business's top-line buoyant.